Cargando…

Qualitative Interviews to Support Development and Cognitive Debriefing of the Adelphi Adherence Questionnaire (ADAQ©): A Patient-Reported Measure of Medication Adherence Developed for Use in a Range of Diseases, Treatment Modalities, and Countries

PURPOSE: The Adelphi Adherence Questionnaire (ADAQ©) is a newly developed generic patient-reported outcome (PRO) assessment of medication adherence. The aim was to assess its content validity by conducting cognitive debriefing (CD) interviews with patients prescribed medication(s) of various treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Bentley, Sarah, Morgan, Lucy, Exall, Elizabeth, Arbuckle, Rob, Rossom, Rebecca C, Roche, Nicholas, Khunti, Kamlesh, Higgins, Victoria, Piercy, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484566/
https://www.ncbi.nlm.nih.gov/pubmed/36133076
http://dx.doi.org/10.2147/PPA.S358046
_version_ 1784791901252091904
author Bentley, Sarah
Morgan, Lucy
Exall, Elizabeth
Arbuckle, Rob
Rossom, Rebecca C
Roche, Nicholas
Khunti, Kamlesh
Higgins, Victoria
Piercy, James
author_facet Bentley, Sarah
Morgan, Lucy
Exall, Elizabeth
Arbuckle, Rob
Rossom, Rebecca C
Roche, Nicholas
Khunti, Kamlesh
Higgins, Victoria
Piercy, James
author_sort Bentley, Sarah
collection PubMed
description PURPOSE: The Adelphi Adherence Questionnaire (ADAQ©) is a newly developed generic patient-reported outcome (PRO) assessment of medication adherence. The aim was to assess its content validity by conducting cognitive debriefing (CD) interviews with patients prescribed medication(s) of various treatment modalities in a range of therapy areas. MATERIALS AND METHODS: Targeted literature/instrument review and concept elicitation interviews informed development of the ADAQ©. CD interviews were conducted with 57 adults from the United States of America (USA; n = 21), Spain (n = 18), and Germany (n = 18) who prescribed medication for hypertension, diabetes, depression, schizophrenia, asthma, multiple myeloma, psoriasis, and/or multiple sclerosis. Interviews were conducted in two rounds to explore the relevance and understanding of the item wording, instructions, recall period and response options. Verbatim transcripts were analysed in ATLAS.Ti using thematic analysis. Three expert clinicians provided guidance throughout the study. RESULTS: ADAQ© items/instructions were well understood and relevant to participants. Key modifications following round 1 included revising instructions to refer to current medication(s) for one condition to reduce cognitive burden, removing two items with lower relevance (specifically those assessing running out of medication and social discouragement), and adding a response option for participants to indicate if they had stopped taking a medication. Minor wording modifications were made following round 2. Subgroup differences in item relevance were explored based on clinical characteristics. Cost of medication was more relevant amongst US participants. CONCLUSION: Content validity of the ADAQ© was confirmed in demographically and clinically diverse participants. Psychometric properties of the ADAQ© will be explored in future studies.
format Online
Article
Text
id pubmed-9484566
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-94845662022-09-20 Qualitative Interviews to Support Development and Cognitive Debriefing of the Adelphi Adherence Questionnaire (ADAQ©): A Patient-Reported Measure of Medication Adherence Developed for Use in a Range of Diseases, Treatment Modalities, and Countries Bentley, Sarah Morgan, Lucy Exall, Elizabeth Arbuckle, Rob Rossom, Rebecca C Roche, Nicholas Khunti, Kamlesh Higgins, Victoria Piercy, James Patient Prefer Adherence Original Research PURPOSE: The Adelphi Adherence Questionnaire (ADAQ©) is a newly developed generic patient-reported outcome (PRO) assessment of medication adherence. The aim was to assess its content validity by conducting cognitive debriefing (CD) interviews with patients prescribed medication(s) of various treatment modalities in a range of therapy areas. MATERIALS AND METHODS: Targeted literature/instrument review and concept elicitation interviews informed development of the ADAQ©. CD interviews were conducted with 57 adults from the United States of America (USA; n = 21), Spain (n = 18), and Germany (n = 18) who prescribed medication for hypertension, diabetes, depression, schizophrenia, asthma, multiple myeloma, psoriasis, and/or multiple sclerosis. Interviews were conducted in two rounds to explore the relevance and understanding of the item wording, instructions, recall period and response options. Verbatim transcripts were analysed in ATLAS.Ti using thematic analysis. Three expert clinicians provided guidance throughout the study. RESULTS: ADAQ© items/instructions were well understood and relevant to participants. Key modifications following round 1 included revising instructions to refer to current medication(s) for one condition to reduce cognitive burden, removing two items with lower relevance (specifically those assessing running out of medication and social discouragement), and adding a response option for participants to indicate if they had stopped taking a medication. Minor wording modifications were made following round 2. Subgroup differences in item relevance were explored based on clinical characteristics. Cost of medication was more relevant amongst US participants. CONCLUSION: Content validity of the ADAQ© was confirmed in demographically and clinically diverse participants. Psychometric properties of the ADAQ© will be explored in future studies. Dove 2022-09-15 /pmc/articles/PMC9484566/ /pubmed/36133076 http://dx.doi.org/10.2147/PPA.S358046 Text en © 2022 Bentley et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Bentley, Sarah
Morgan, Lucy
Exall, Elizabeth
Arbuckle, Rob
Rossom, Rebecca C
Roche, Nicholas
Khunti, Kamlesh
Higgins, Victoria
Piercy, James
Qualitative Interviews to Support Development and Cognitive Debriefing of the Adelphi Adherence Questionnaire (ADAQ©): A Patient-Reported Measure of Medication Adherence Developed for Use in a Range of Diseases, Treatment Modalities, and Countries
title Qualitative Interviews to Support Development and Cognitive Debriefing of the Adelphi Adherence Questionnaire (ADAQ©): A Patient-Reported Measure of Medication Adherence Developed for Use in a Range of Diseases, Treatment Modalities, and Countries
title_full Qualitative Interviews to Support Development and Cognitive Debriefing of the Adelphi Adherence Questionnaire (ADAQ©): A Patient-Reported Measure of Medication Adherence Developed for Use in a Range of Diseases, Treatment Modalities, and Countries
title_fullStr Qualitative Interviews to Support Development and Cognitive Debriefing of the Adelphi Adherence Questionnaire (ADAQ©): A Patient-Reported Measure of Medication Adherence Developed for Use in a Range of Diseases, Treatment Modalities, and Countries
title_full_unstemmed Qualitative Interviews to Support Development and Cognitive Debriefing of the Adelphi Adherence Questionnaire (ADAQ©): A Patient-Reported Measure of Medication Adherence Developed for Use in a Range of Diseases, Treatment Modalities, and Countries
title_short Qualitative Interviews to Support Development and Cognitive Debriefing of the Adelphi Adherence Questionnaire (ADAQ©): A Patient-Reported Measure of Medication Adherence Developed for Use in a Range of Diseases, Treatment Modalities, and Countries
title_sort qualitative interviews to support development and cognitive debriefing of the adelphi adherence questionnaire (adaq©): a patient-reported measure of medication adherence developed for use in a range of diseases, treatment modalities, and countries
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484566/
https://www.ncbi.nlm.nih.gov/pubmed/36133076
http://dx.doi.org/10.2147/PPA.S358046
work_keys_str_mv AT bentleysarah qualitativeinterviewstosupportdevelopmentandcognitivedebriefingoftheadelphiadherencequestionnaireadaqapatientreportedmeasureofmedicationadherencedevelopedforuseinarangeofdiseasestreatmentmodalitiesandcountries
AT morganlucy qualitativeinterviewstosupportdevelopmentandcognitivedebriefingoftheadelphiadherencequestionnaireadaqapatientreportedmeasureofmedicationadherencedevelopedforuseinarangeofdiseasestreatmentmodalitiesandcountries
AT exallelizabeth qualitativeinterviewstosupportdevelopmentandcognitivedebriefingoftheadelphiadherencequestionnaireadaqapatientreportedmeasureofmedicationadherencedevelopedforuseinarangeofdiseasestreatmentmodalitiesandcountries
AT arbucklerob qualitativeinterviewstosupportdevelopmentandcognitivedebriefingoftheadelphiadherencequestionnaireadaqapatientreportedmeasureofmedicationadherencedevelopedforuseinarangeofdiseasestreatmentmodalitiesandcountries
AT rossomrebeccac qualitativeinterviewstosupportdevelopmentandcognitivedebriefingoftheadelphiadherencequestionnaireadaqapatientreportedmeasureofmedicationadherencedevelopedforuseinarangeofdiseasestreatmentmodalitiesandcountries
AT rochenicholas qualitativeinterviewstosupportdevelopmentandcognitivedebriefingoftheadelphiadherencequestionnaireadaqapatientreportedmeasureofmedicationadherencedevelopedforuseinarangeofdiseasestreatmentmodalitiesandcountries
AT khuntikamlesh qualitativeinterviewstosupportdevelopmentandcognitivedebriefingoftheadelphiadherencequestionnaireadaqapatientreportedmeasureofmedicationadherencedevelopedforuseinarangeofdiseasestreatmentmodalitiesandcountries
AT higginsvictoria qualitativeinterviewstosupportdevelopmentandcognitivedebriefingoftheadelphiadherencequestionnaireadaqapatientreportedmeasureofmedicationadherencedevelopedforuseinarangeofdiseasestreatmentmodalitiesandcountries
AT piercyjames qualitativeinterviewstosupportdevelopmentandcognitivedebriefingoftheadelphiadherencequestionnaireadaqapatientreportedmeasureofmedicationadherencedevelopedforuseinarangeofdiseasestreatmentmodalitiesandcountries